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Abstract
Aims Clinical outcomes for patients suspected of having heart failure (HF) who do not meet the diagnostic criteria of any
type of HF by echocardiography remain unknown. The aim of this study was to investigate the clinical predictors of
all-cause mortality in patients with suspected HF, a raised N-terminal pro-b-type natriuretic peptide (NTproBNP) and who
do not meet the diagnostic criteria of any type of HF by echocardiography.
Methods and results Relevant data were taken from the Sheffield HEArt Failure (SHEAF) registry (222349P4). The inclusion
criteria were presence of symptoms raising suspicion of HF, NTproBNP > 400 pg/mL, and preserved left ventricular function.
Exclusion criteria were any type of HF by echocardiography. The outcome was defined as all-cause mortality. Cox
proportional-hazards regression model was used to investigate the association between the survival time of patients and clin-
ical variables; 1031 patients were identified with NTproBNP > 400 pg/mL but who did not have echocardiographic evidence of
HF. All-cause mortality was 21.5% (222 deaths) over the mean follow-up (FU) period of 6 ± 2 years. NTproBNP was similar in
patients who were alive or dead (P = 0.96). However, age (HR 1, P < 0.01), chronic kidney disease (CKD, HR 1.2, P < 0.01),
chronic pulmonary obstructive disease (COPD, HR 1.6, P < 0.01), dementia (HR 5.9, P < 0.01), male gender (HR 1.4,
P < 0.01), first-degree atrioventricular block (HR 2.1, P < 0.01), left axis deviation (HR 1.6, P = 0.04), and diabetes (HR 1.4,
P = 0.03) were associated with all-cause mortality. In multivariate regression, age, gender, CKD stage, COPD, and dementia
were independently associated with mortality. In patients with NTproBNP > 627 pg/mL, NYHA class predicted death (II,
19.6%; III, 27.4%; IV, 66.7%; P < 0.01).
Conclusions Patients with no HF on echocardiography but raised NTproBNP suffer excess mortality particularly in the pres-
ence of certain clinical variables. Age, male gender, worsening CKD stage, presence of COPD, and dementia are independently
associated with all-cause mortality in these patients. An NTproBNP > 627 pg/mL coupled with NYHA class could identify pa-
tients at greatest risk of death.
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Introduction
The prevalence of heart failure (HF) is rising,1 mainly because
of a significant increase in HF with preserved ejection fraction
(HFpEF)2 and the ageing population. In addition, survival after
a diagnosis of HF has shown only modest improvement in the
last decade.3 Many of the symptoms and clinical signs of HF
are non-specific, hence, the need for additional tests to con-
firm that symptoms are caused by structural and/or
functional abnormalities of the heart. Routinely, N-terminal
pro-b-type natriuretic peptide (NTproBNP) and transthoracic
echocardiography (TTE) are used to confirm the diagnosis of
HF. While NTproBNP is mainly used as a screening test for
HF and a prognostic tool in HF, TTE is used to detect
ORIG INAL RESEARCH ART ICLE
© 2020 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of the European Society of Cardiology
ESC HEART FAILURE
ESC Heart Failure (2020)
Published online in Wiley Online Library (wileyonlinelibrary.com) DOI: 10.1002/ehf2.12742
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the
original work is properly cited.
structural and functional indicators suggestive of HF and its
underlying causes.4,5
Those patients presenting to the HF diagnostic clinic with
suspicion of HF and rise of the NTproBNP >400 pg/mL,
whose echocardiograms do not meet the diagnostic criteria
of any of the types of HF are thought not to have HF. We
know that the rise of NTproBNP is associated with worsening
prognosis even if the patient does not have HF.6 It would be
of clinical importance to characterise the group of patients
with raised NTproBNP who are deemed not to have HF.
Moreover, there is particular anxiety related to the rise in
the incidence and prevalence of HFpEF, especially given the
fact their diagnosis is dependent on indirect markers of the
rise of the left ventricular end-diastolic pressure. In other
words, one needs to ensure that no one with HFpEF is
misdiagnosed as not having HF. The clinical profile of patients
with HFpEF remains varied and is evolving over time. More-
over, it remains unclear if patients who do not seem to meet
the criteria of HFpEF by current methods have any significant
increase in long-term mortality.
This study sought to investigate the clinical profile and out-
comes of patients presenting with symptoms or signs that
may suggest HF, a raised NTproBNP and no echocardio-
graphic evidence of HF.
Methods
Data and patients
Patients in Sheffield with a suspected diagnosis of HF from a
population of 550 000 are screened by primary care physi-
cians using a single measurement of NTproBNP. In accor-
dance with the National Institute of Health and Care
Excellence (NICE) guidelines those with a positive
NT-proBNP and symptoms or signs that may suggest HF are
referred to the diagnostic HF clinic in Sheffield, UK.7,8 Data
are collected prospectively and electronically encrypted with
an annual data validation check. The analytical cohort was de-
rived from all patients presenting to the regional HF unit be-
tween 13 April 2012 and 28 November 2018. Inclusion
criteria for this study were the following: age 18 years or
over, raised NTproBNP (>400 pg/mL) and preserved LV func-
tion. Exclusion criteria included any type of HF including
HFpEF, HF secondary to a mid range reduction in EF (HFmEF)
or HF with reduced EF (HFrEF), significant valvular heart dis-
ease or pulmonary hypertension. Patients who did not have
full echocardiographic study were excluded from this study.
Heart failure assessment
All patients referred to the HF clinic from primary care had
NTproBNP equal to or higher than 400 pg/mL. All patients
underwent a resting 12-lead electrocardiogram and a TTE ex-
amination. After these tests, each patient was clinically
assessed by a HF specialist. The final diagnosis was deter-
mined by the responsible HF specialist according to the pre-
senting history, clinical examination, and the results of
investigations in keeping with NICE chronic HF guidelines.7,9
Echocardiography
Echocardiography was performed as per the consensus state-
ment. Both the clinical physiologist performing the echocar-
diogram and the treating cardiologist were involved to
make the final integrated diagnosis of a form of HF or no ev-
idence of HF if the left ventricle was preserved, and there was
no evidence of raised LV filling pressure.
Research ethics
The Sheffield HEArt Failure registry (SHEAF registry) has been
sanctioned by the local 3D lab committee under the registra-
tion number—222349P4. This has the appropriate research
ethics committee approval (17/YH/0142). This study complies
with the Declaration of Helsinki.
Study variables
Clinical variables were extracted from the regional electronic
HF database: patient demographics (age, sex, and date of first
contact with HF services), past medical history [systemic
hypertension, diabetes, ischaemic heart disease, hyperlipid-
aemia, smoking status, valve disease, chronic obstructive pul-
monary disease (COPD), peripheral vascular disease,
pulmonary embolus, prior coronary or valvular intervention,
dementia, and stroke], and clinical symptom burden defined
by New York Heart Association (NYHA) functional status and
presence of any angina. Renal functional stratification was
made using the chronic kidney disease (CKD) stages on renal
biochemistry tests and recorded in the HF database10.
NTproBNP was recorded in all patients. The NTproBNP assay
used was the Roche NT-Pro BNP assay. CV is 5% at concentra-
tions of 130 and 4000.
The 12-lead electrocardiogram documented rhythm (sinus,
atrial fibrillation, or paced), QRS duration, left axis deviation,
ST/T-wave changes, presence of ectopic beats, any conduc-
tion delays or atrioventricular blocks (AVB), and presence of
LV hypertrophy using the standard voltage criteria11. Simi-
larly, details of the echocardiographic findings were regis-
tered in the database.
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Statistical analysis
Statistical analyses were performed in IBM SPSS version
25.0, 64 bits and MedCalc version 19.0.5. Categorical base-
line characteristics are described with numbers and per-
centages. Continuous variables are described using means
and standard deviation (SD). The outcome was defined as
all-cause mortality. All continuous variables were compared
to death using independent sample T-test. Categorical vari-
ables were compared using χ2 T-test. Initially, the unad-
justed association of mortality was calculated in a
univariate logistic regression model, and results presented
as hazard ratios [HRs, 95% CI (confidence interval)]. Forest
plot was used to visualise the significance of individual clin-
ical variables. A subgroup total was calculated as the aver-
age of relative risks and CIs to check for overall
significance. The univariable χ2 values tested the strength
of these associations and permitted benchmark compari-
sons between clinical measures in models where higher
values equate stronger associations and lower P values.
Subsequently, the Cox proportional-hazards regression
model was used to investigate the association between
the survival time of patients and clinical variables signifi-
cance in univariate analysis (P < 0.05). Kaplan–Meier
curves are used to visualise and interpret the data of vari-
ables associated with mortality. Kaplan–Meier curves used
the log-rank test to investigate the differences in curves be-
tween alive and dead patients at FU. Finally, c-statistics de-
termined the threshold of NTproBNP for its association to
mortality in patients using the Youden index criterion value
from the receiver operating curve (ROC) analysis investigat-
ing its association to all-cause mortality. The NTproBNP
threshold was then used to investigate the association of
HF symptom burden defined by NYHA functional class and
all-cause mortality. The Kruskal–Wallis one-way ANOVA test
was used to investigate the overall differences in mortality
rates between different NYHA functional classes. All tests
were two-sided, and statistical significance was considered
P < 0.05.
Results
Patient characteristics
Baseline characteristics of the cohort are summarised in
Table 1. We identified 1031 patients who presented to the re-
gional HF services with raised NTproBNP with normal LV fill-
ing pressure on TTE, normal contraction, and no valvular
abnormalities with no sign of pulmonary hypertension or
right ventricular impairment. The mean age of the study pop-
ulation was 76.5 ± 9 years, and 55.5% were women. The av-
erage NTproBNP was 939.5 ± 865 pg/mL. From the total
cohort, 34% (n = 352) patients were in AF. The AF patient
population had significantly higher NTproBNP levels when
compared to non-AF patients (1192 ± 827 pg/mL vs.
797 ± 852 pg/mL, P < 0.05). The average follow-up time
was 6 ± 2 years for all patients. The all-cause mortality in
our study was 21.5% (222 deaths). From the whole cohort,
47% were on β-blockers, 38% on angiotensin converting en-
zyme inhibitors, 4% on mineralocorticoid antagonists, and
3% on diuretics.
Association of clinical parameters to all-cause
mortality
As expected, during follow-up, mortality was higher in more
elderly patients (P < 0.01) (Table 1). NTproBNP at presenta-
tion was similar in the no-morality and mortality group
(P = 0.96). A greater number of female patients presented
to HF clinic; however, male patients had greater all-cause
mortality (25.3% vs. 18.5%, P < 0.01).
Of the 13 recorded ECG parameters, three parameters
were significantly different between those with all cause mor-
tality and those who survived. First-degree atrioventricular
block (AVB) and left axis deviation were more common in pa-
tients with all cause mortality (9% vs. 4% [P<0.01] and 9% vs.
5% [P=0.02], respectively). Whereas AF was less common in
patients with all cause mortality (14% vs. 26%, P<0.05).The
latter remained the case even when we looked at patients
with AF and higher NTproBNP levels (>797pg/mL) than
non-AF patients (14.1% mortality vs. 25.5% mortality, P
<0.001).
Advancing CKD stage was also associated with a rise in
all-cause mortality. Among the other co-morbidities diabetes
mellitus type 2, COPD and dementia were more prevalent in
patients with all-cause mortality.
Regression
Univariate regression identified eight variables associated
with all-cause mortality—age, advancing CKD stages, history
of COPD, history of dementia, male gender, first-degree
AVB, left axis deviation, and history of diabetes mellitus
(Table 2, Figure 1). Multivariate cox proportional-hazards re-
gression identified five variables with independent associa-
tion to all-cause mortality—age, advancing CKD stages,
history of COPD, history of dementia, and male gender, of
which dementia was the most closely related to mortality
(24.8, HR 6.1; 95% CI: 3–12.6).
Kaplan–Meier and log-rank analysis demonstrated signifi-
cantly worse survival curves for male patients as well as pa-
tients with dementia, COPD, and advancing stages of CKD
(Figure 2).
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NYHA burden and mortality
The optimum threshold for NTproBNP on c-statistics was
627 pg/mL for association to mortality in our cohort
(AUC:0.51, 95% CI: 0.48 to 0.54; P = 0.64). In patients with
NTproBNP higher than 627 pg/mL, we noted that
worsening NYHA functional class was associated with
all-cause mortality (NYHA II, 19.6% mortality; NYHA III,
27.4% mortality; and NYHA IV, 66.7% mortality; P-
value = 0.01) (Table 3). Conover post hoc analysis revealed
Table 2 Cox proportional-hazards regression of all the clinical variables which had significant association to all-cause mortality
Univariate model Multivariate model
χ
2
value HR (95% CI) P-value χ
2
value HR (95% CI) P-value
Age (years) 29.3 1 (1–1.1) <0.001 23 1 (1–1.1) <0.001
CKD (Stages 0–5) 11.1 1.2 (1–1.3) <0.001 5.3 1.12 (1–1.2) 0.02
COPD* 10.7 1.6 (1.2–2.2) 0.001 13 1.7 (1.3–2.3) <0.001
Dementia* 24.1 5.9 (2.9–11.9) <0.001 24.8 6.1(3–12.6) <0.001
Gender 6.9 1.4 (1.1–1.9) 0.009 8.7 1.5 (1.1–1.9) 0.003
1st-degree AVB* 10.1 2.1 (1.3–3.3) 0.001 - - -
Left axis deviation* 4.1 1.6 (1–2.5) 0.04 - - -
Diabetes mellitus* 4.7 1.4 (1–2) 0.03 - - -
The single asterisks denote the clinical variables that showed significant association with all cause mortality as shown on the Forest plot in
Figure 1.
Table 1 Demographics of the study population sub-categorised depending on mortality at 6-year follow-up
Alive Dead P-value
% (N) 78.5 (809) 21.5 (222)
Age (years) 76 ± 9 79 ± 8 <0.01
NT-pro BNP (pg/mL) 939 ± 866 942 ± 863 0.96
Male % (N) 42 (343) 52 (116) <0.01
12 lead electrocardiographic findings
Sinus rhythm % (N) 61 (493) 76 (169) <0.01
Atrial fibrillation % (N) 37 (303) 22 (49)
Paced % (N) 2 (13) 2 (4)
QRS < 120 msec % (N) 93 (749) 90 (199) 0.23
QRS = 120–150 msec % (N) 5 (44) 9 (19)
QRS > 150 msec % (N) 2 (16) 2 (4)
Left axis deviation % (N) 5 (41) 9 (20) 0.02
Ectopic beats % (N) 2 (19) 3 (7) 0.49
1st-degree AVB % (N) 4 (31) 9 (21) <0.01
Higher degree AVB % (N) 1 (6) 1 (2) 0.81
T-wave inversion % (N) 5 (41) 6 (13) 0.64
ST-segment changes % (N) 4 (29) 6 (13) 0.13
Voltage criteria of LV hypertrophy % (N) 3 (23) 4 (9) 0.35
Symptoms burden
NYHA I % (N) 30 (246) 34 (75) 0.05
NYHA II % (N) 59 (478) 51 (114)
NYHA III % (N) 10 (81) 13 (29)
NYHA IV % (N) 1 (4) 2 (4)
Angina % (N) 14 (113) 15 (34) 0.26
Risk factors for heart disease
CKD 0% (N) 41 (331) 29 (64) 0.01
CKD 1% (N) 9 (69) 11 (24)
CKD 2% (N) 15 (122) 16 (35)
CKD 3% (N) 33 (264) 39 (87)
CKD 4% (N) 2 (20) 4 (9)
CKD 5% (N) 0 (3) 1 (3)
Ischaemic heart disease % (N) 25 (200) 25 (56) 0.87
Valvular heart disease % (N) 7 (55) 10 (23) 0.07
Systemic Hypertension % (N) 62 (498) 63 (140) 0.68
Diabetes % (N) 14 (115) 20 (44) 0.04
Hypercholesterolaemia % (N) 17 (136) 14 (30) 0.24
Smoker % (N) 28 (223) 24 (54) 0.33
COPD % (N) 18 (147) 28 (63) <0.01
Dementia % (N) 0 (2) 4 (8) <0.01
Stroke % (N) 10 (82) 14 (31) 0.11
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significant differences within each NYHA symptomatic group
(Figure 3).
NTproBNP and clinical variables associated with
all-cause mortality
As expected from the literature, NTproBNP was significantly
higher in males versus females [734 pg/mL, interquartile
range (IQR): 1180–513 vs. 639 pg/mL, IQR: 998–481;
P < 0.001] (see Supporting Information, Figure S1). Similarly,
with advancing CKD stages, there was a significant rise in
NTproBNP (P < 0.001). In post hoc analysis, NTproBNP levels
for CKD Stages 0 to 2 were significantly lower than for CKD
Stages 3 to 5 (P < 0.05). NTproBNP levels for patients in
CKD Stage 1 were significantly lower than the levels for pa-
tients in CKD Stages 4 and 5 (P < 0.05). NTproBNP levels in
patients with CKD Stage 4 were significantly lower than the
levels in patients with CKD Stage 5 (833, IQR: 1255–695 vs.
3808, IQR: 10 415–1356, P < 0.05).
However, NTproBNP levels was comparable in patients
with and without COPD (683 pg/mL, IQR: 965–502 vs.
663 pg/mL, IQR: 1122–492; P = 0.64) and those with or with-
out dementia (514 pg/mL, IQR: 703–432 vs. 668 pg/mL, IQR:
1102–494; P = 0.14).
Discussion
In this study, we demonstrate that patients with suspected
HF who present with raised NTproBNP, but whose
echocardiogram does not suggest the presence of any form
of HF including HFpEF, have high all-cause mortality over a
mean FU period of 6 years. Clinical factors which were asso-
ciated with all-cause mortality included age, male gender,
left-axis deviation, first-degree heart block, advancing CKD
stages, history of diabetes mellitus, COPD, and dementia.
However, clinical factors which were independently associ-
ated with all-cause mortality were age, male gender, CKD
stage, COPD, and dementia. It was noteworthy that using a
higher threshold of NTproBNP of 627 pg/mL, worsening
NYHA function class was associated with poorer outcomes.
This study highlights that these patients warrant further clin-
ical attention and calls for potential future studies to investi-
gate if they truly do not have raised LV filling pressures that
may define HFpEF.
The prognostic role of NT-proBNP in the general popula-
tion remains controversial. However, a recent meta-analysis
of eight studies investigating the role of NT-proBNP for prog-
nostication in the general population, concluded that
NT-proBNP levels are associated with all-cause mortality12.
In the eight studies which reported all-cause mortality in
the general population, over an average follow-up period of
7 years, the mortality was 16%. This is less than the mortality
we report at 21.5%. Importantly, the authors of the
meta-analysis also noted that the risk of all-cause mortality
was higher in studies with a follow-up duration ≤5 years than
in those with >5 years of follow-up, suggesting death events
mainly occurs in the early follow-up duration. Our study has
many differences to general population-based studies. Firstly,
our patient population only includes patients who have
Figure 1 Forest plot demonstrating relative risk (orange box) and its 95% CI (black line) of clinical variables that demonstrated association with
all-cause mortality (P < 0.05). The subtotal relative risk was 2 (95% CI: 1.3–3.3).
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suspected HF because of symptoms or signs and raised
NTproBNP who have been referred by primary care physi-
cians for specialist advice. Secondly, our follow-up period
was longer than 5-years, and this may explain why we did
not demonstrate overall significant association between
NTproBNP levels and mortality. The question remains as to
whether some of these patients may still develop HF at a
later stage and that the initial assessment despite their symp-
toms or signs could not detect any echocardiographic evi-
dence of HF of any type.
The mortality rate for HFpEF from previously published
studies remains unacceptably high—32% at 3–4 years follow-
up. In our study, we demonstrate that the all-cause mortality
rate for the people who were not found to have HF was lower
at 21.5% for a mean FU period of 6 years. When we looked at
patients with the higher threshold of NTpro-BNP (627 pg/mL),
and investigated their all-cause mortality rates, patients with
NYHA III demonstrated a mortality rate of 27.5%, which is
not too far from the mortality rate of patients with HFpEF, de-
scribed in the literature. Importantly, patients with NYHA IV
symptoms had more than double the all-cause mortality rates
at 66.7%. This suggests that in patients who do not have evi-
dence of any other type of HF, but have a high burden of symp-
toms with significantly raised NTproBNP, further tests may be
needed, and perhaps careful follow-up of these patients
should be considered given their high risk of events.
Figure 2 Kaplan–Meier (KM) plots for the risk of all-cause mortality (n = 222) in the SHEAF registry of 1031 patients with raised NTproBNP and no ev-
idence of HFpEF on TTE. Panel (a) demonstrates the KM plots for gender and the significantly increased incidence of mortality in men. Panel (b) dem-
onstrates increased mortality with worsening CKD stages. Panel (c) demonstrates COPD is associated with worsening mortality. Panel (d) demonstrates
that a diagnosis of dementia in this cohort is associated with poorer outcomes.
Table 3 In patients with raised NTproBNP over the threshold, increasing HF symptom burden demonstrated association with increasing
all-cause mortality
NYHA class Alive at FU Dead at FU χ
2
(P-value) χ
2
for trend (P-Value)
II 266 (80.4%) 65 (19.6%) 9.2 (P = 0.01) 6.7 (P < 0.01)
III 45 (72.6%) 17 (27.4%)
IV 2 (33.3%) 4 (66.7%)
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Previous studies have shown that cardiovascular magnetic
resonance (CMR) can provide tissue characterisation in HFpEF
to further sub-phenotype HFpEF13. Kanagala et al. made the
point that CMR can detect previously undiagnosed pathology
by echocardiography in 27% patients. Most importantly, a
new CMR diagnosis was the strongest independent predictor
of adverse outcome (HR: 1.92; 95% CI: 1.07 to 3.45; P = 0.03)
in their study.
The mean age of patients in our study is greater than
76 years. Not unexpectedly advancing age independently pre-
dicted all-cause mortality, although the patients who died
during up to 6-year follow up were only 3 years older than
patients who were alive (76 vs. 79 years old). Gender strongly
influences the outcomes in various cardiovascular diseases14.
In comparison to our study, general population based studies
have reported varying death rate in the elderly population
above the age of 70 (20% in early 70s to 35% in late 70s)15.
Moreover, in the elderly, symptoms of reduced effort toler-
ance or shortness of breath are often poorly reported,16,17
and hence, it remains unclear how many patients from the
general population are in the high risk. What is obvious is that
the elderly with increased symptom burden, especially short-
ness of breath, have significantly higher mortality18,19.
Recent evidence from epidemiological studies suggests
that male patients with HFpEF tend to have a worse clinical
course20. Similarly, this study demonstrates that male pa-
tients who have raised NTproBNP and no evidence of HF on
echocardiography, have 8% increase in all-cause mortality
when compared to their female counterparts. Compared with
Lam et al.’s sub-study of ‘The Irbesartan in Heart Failure With
Preserved Ejection Fraction (I-PRESERVE)’ Trial which evalu-
ated gender difference in HFpEF, our HR for male gender
was slightly higher for all-cause mortality when compared
to their study (1.4 vs. 1.025). Another study by Duca et al.,
demonstrated increased cardiac death but not all-cause mor-
tality in male patients with HFpEF when compared with their
female counterparts. Our study also demonstrates that the
overall NTproBNP levels were higher in men at presentation
than in women (see Supporting Information, Figure S1). How-
ever, this is not surprising as female gender is known to be
associated with lower levels of NTproBNP, when compared
with men in the general population.
One of the key negative findings of this study is that
NTproBNP alone does not predict mortality in patients who
have no evidence of HF by echocardiography. However, when
it is taken into account with the symptom burden, assessed
as NYHA functional class, it does appear to have a compli-
mentary role. In our study, higher threshold for NTproBNP
(>627 pg/mL) and increasing NYHA functional class, were as-
sociated with increasing mortality. Hence, patients with
higher degree of symptoms should not be ignored and fur-
ther tests to confirm no HF may be necessary in this patient
population.
There is limited literature which has investigated the clini-
cal relevance of ECG changes in HFpEF21,22. The study carried
out by Cenkerova et al. demonstrated that HFpEF patients
who died during the course of FU, had a tendency to have
a prolonged QTc interval (427 ± 42 ms vs. 454 ± 42 ms,
P = 0.058)21. Another study comparing HFpEF with HF be-
cause of reduced ejection fraction (HFrEF) for ECG changes,
demonstrated that higher resting heart rate, abnormal
P-wave axis, and abnormal QRS-T axis were associated with
HFpEF22. However, this study did not look at mortality as pri-
mary end-point and only compared ECG in the two HF states.
Contrary to both these studies, our study investigated the
most commonly reported ECG abnormalities. We noted that
Figure 3 A significant rise in all-cause mortality with higher symptom burden (NYHA class II-IV) in patients with no evidence of HF on
echocardiography.
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left axis deviation and first-degree AVB were the only two
ECG markers associated with all-cause mortality. Left axis de-
viation has been shown in both population-based studies23
and in acute HF24 to be associated with all-cause mortality.
Certainly, its role in cohorts of patients who do not have
echocardiographic evidence of any type of HF though they
have symptoms suspicious of HF and raised NTproBNP, like
our cohort, had not been previously studied.
Our study did not demonstrate an increase in mortality in
patients with AF. We suspect this is probably because these
patients are reviewed and managed by specialists who fur-
ther optimised their therapy as required.
Worsening CKD stage is a well-established marker of
poorer outcomes and all-cause mortality25,26. It is also known
that the higher the CKD stage, the higher the baseline of
NTproBNP would be27. NTproBNP is excreted from the kidney
in the active form or as metabolites. In case of worsening re-
nal function, NTproBNP levels are likely to go up. This will be
even more pronounced in patients who have raised
intra-cardiac pressures. Results from this study demonstrate
a similar association of CKD stage and all-cause mortality in
patients with no evidence of HF or raised LV filling pressure.
Hence, the rise in all-cause mortality may be in part related
to CKD plus the functional decline identified by NYHA func-
tional class in our study. It is worth noting that at advanced
stages of renal impairment (CKD Stages 4–5), NTproBNP rises
steeply highlighting the importance of looking at altering the
NTproBNP thresholds based on co-morbidities such as CKD.
Limitations
First, this observational study includes data from a single cen-
tre. However, the SHEAF registry includes diverse data of HF
patients from Sheffield in England. Even though the ethnic
background of patients was not recorded, this region of En-
gland is ethnically very diverse (Asian: 7.3%, black: 1.5%,
mixed: 1.6% white: 85.8% and other: 3%)28. Second, as this
is an observational study, the results of this study are mainly
hypothesis-generating. Further prospective studies are
warranted to investigate and ascertain the phenotype of
the patients with breathlessness, raised NTproBNP, and nor-
mal TTE. Cardiovascular magnetic resonance imaging
has demonstrated some promise to better categorise dia-
stolic function29–34; however, this needs further invasive
catheter-based validation studies. Third, this study did not re-
cord the cause of death.
Conclusion
Symptomatic patients with no HF but raised NTproBNP and
normal LV filling pressure on echocardiography suffer excess
mortality, particularly in the presence of certain clinical
variables. Age, male gender, worsening CKD stage, presence
of COPD, and dementia are independently associated
with all-cause mortality in these patients. An
NTproBNP>627 pg/mL coupled with NYHA class could iden-
tify patients at greatest risk of death. Further studies are
needed to better sub-phenotype this group of patients and
determine any underlying aetiology that may warrant further
intervention.
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